Symbio Upfront Payment was Traws Pharma’s largest revenue line in fiscal 2017, bringing in $455.00K of $787.00K (58%).
| Products and Services | FY 2017 |
|---|---|
| Symbio Upfront Payment | $455.00K |
| Supplies | $332.00K |
| Total | $787.00K |
Traws Pharma brought in $787.00K from its two revenue lines in fiscal 2017, the year ended December 31, 2017. Symbio Upfront Payment was the largest at $455.00K (57.8%), ahead of Supplies at $332.00K (42.2%).
Traws Pharma (TRAW) reports its revenue by products and services. In fiscal 2017, Symbio Upfront Payment was its largest revenue line, bringing in $455.00K (57.8% of the total), followed by Supplies at $332.00K (42.2%).
Symbio Upfront Payment was Traws Pharma's largest revenue line in fiscal 2017, bringing in $455.00K, or 57.8% of the $787.00K total across its two revenue lines.
Every figure comes from Traws Pharma's annual financial filings, as reported. Each line keeps the name Traws Pharma gives it, and years follow its fiscal calendar.
Traws Pharma's revenue by products and services goes back to fiscal 2017, with figures through fiscal 2017. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.